Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as APL-3007, pegcetacoplan (APL-2)
APL-3007, pegcetacoplan · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Group 1 (APL-3007 Dose/Frequency 1 ) | EXPERIMENTAL | APL-3007 SC + pegcetacoplan (APL-2) |
| Group 2 (APL-3007 Dose/Frequency 2) | EXPERIMENTAL | APL-3007 + pegcetacoplan (APL-2) |
| Group 3 (placebo) | PLACEBO_COMPARATOR | Placebo SC + pegcetacoplan (APL-2) |
| Name | Type | Description |
|---|---|---|
| APL-3007, pegcetacoplan (APL-2) | DRUG | Complement C3 inhibitor |
| Placebo, Syfovre | OTHER | Complement C3 Inhibitor |
Inclusion Criteria: * The study eye must meet all inclusion criteria. If both eyes meet the inclusion criteria, the eye with better normal luminance visual acuity at the screening visit will be designated as the study eye. If both eyes have the same visual acuity, the right eye will be used as the ...
APL-3007 is an investigational small molecule being studied for the treatment of Geographic Atrophy Secondary to Age-related Macular Degeneration. It is currently in Phase 2 clinical development and is not yet approved by regulatory authorities.
APL-3007 is being developed by Apellis Pharmaceuticals, Inc., a biopharmaceutical company listed on the NASDAQ under the ticker symbol APLS. The company is conducting clinical trials to evaluate the drug's efficacy and safety in patients with Geographic Atrophy Secondary to Age-related Macular Degeneration.
APL-3007 is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. The ongoing Phase 2 trial is recruiting participants to evaluate the drug's efficacy, safety, and pharmacodynamics.
APL-3007 is being evaluated in a Phase 2, randomized, placebo-controlled, multicenter, masked study with the identifier NCT07215390. The trial is recruiting 240 participants in the United States to assess the efficacy, safety, tolerability, and pharmacodynamics of multidose APL-3007 in combination with Syfovre/Pegcetacoplan (APL-2) in patients with Geographic Atrophy Secondary to Age-related Macular Degeneration.
APL-3007 is also known as pegcetacoplan (APL-2). The drug is being studied in combination with Syfovre/Pegcetacoplan (APL-2) in the ongoing Phase 2 clinical trial, indicating that APL-3007 is a distinct investigational agent being evaluated alongside pegcetacoplan.